Intrials wants to make Latin America a global hub for clinical trials and plans to take on more complex, larger drug studies.
The Brazilian clinical research organization (CRO) announced its intention last week citing its new deal with tech supplier Medidata as a key component.
Intrials president Sergio Braga Filho said “the technology from Medidata drives our success in bringing new clinical studies to Latin America by automating our workflow and streamlining manual processes.
“This is a tremendous opportunity to make our region a showcase for clinical research and the development of therapies to benefit patients.”
Under the deal – financial terms of which were not provided - the CRO will use Medidata’s CTMS, trial master file and site payment systems.
Intrials specializes in recruitment and clinical research across Latin America and has offices in Brazil, Chile, Peru, Colombia, Mexico, and Argentina.
Joan Shaiman, senior vice president at Medidata, said the agreement with Intrials was in keeping with increasing demand the tech firm has seen from drug developers working in the region.
“As our sponsors extend their studies in emerging markets in Latin America, they now have a Medidata CRO partner with a growing presence in the region with the same platform they rely on around the world.
Shaiman predicted that “our solutions give Intrials a competitive advantage, with efficiencies in trial enrollment, site payments, and trial start-up to serve their customers and bring drugs to market faster.”
Latin American landscape
According to analysis published on the Statistica website as of June 2023, Brazil led the ranking of Latin American countries with most clinical trials, with over 9,000 studies.
Mexico ranked second, with nearly 5,000 clinical trials. Brazil concentrated 1.9% of the clinical trials performed worldwide regarding autoimmune and inflammatory diseases in 2021.